NeuroSense Therapeutics Ltd. received U.S. Patent No. 12,527,768 on January 21 2026, covering its fixed‑dose combination of ciprofloxacin and celecoxib for treating Alzheimer’s disease. The grant extends protection through 2043, giving the company a 17‑year window of market exclusivity for PrimeC in the United States.
The patent strengthens NeuroSense’s intellectual‑property portfolio for its lead candidate, PrimeC, which has already demonstrated a favorable safety profile in a Phase 2 proof‑of‑concept study (RoAD). The RoAD study concluded its safety analysis on December 2025, with full efficacy results expected in the first quarter of 2026. The new patent supports the company’s strategy to advance PrimeC into later‑stage trials and to pursue commercialization in the U.S. and abroad.
PrimeC’s dual‑mechanism approach targets both neuroinflammation and amyloid pathology, leveraging the anti‑inflammatory properties of celecoxib and the antimicrobial activity of ciprofloxacin. The combination is delivered as an extended‑release oral formulation, allowing once‑daily dosing and potentially improving adherence in the Alzheimer’s population.
The patent grant also complements PrimeC’s orphan‑drug designation from the FDA and EMA, positioning the company to negotiate pricing and reimbursement agreements with payers. By securing durable protection, NeuroSense can better forecast revenue streams and attract strategic partners or investors for later‑stage development.
Management emphasized the significance of the patent: “This patent meaningfully expands and reinforces our intellectual property position around the PrimeC combination. It reflects both the breadth of the underlying biology and our strategy to build durable protection as we advance PrimeC combination clinically in Alzheimer’s disease and other neurodegenerative conditions,” said Alon Ben‑Noon, Co‑Founder and CEO.
The company’s broader IP portfolio includes patents in Canada, Australia, and Europe, with protection generally extending through 2038 or 2042. The U.S. grant’s 2043 expiration provides the longest exclusivity period among the regions, giving NeuroSense a competitive advantage in the U.S. market.
While the company remains cash‑constrained, with $3.4 million in cash as of December 31 2024, the patent grant enhances its negotiating position for future funding rounds or partnership deals. Analysts view the patent as a key milestone that could unlock additional capital and accelerate PrimeC’s path to market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.